Literature DB >> 26719529

Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.

Noël J-M Raynal1, Justin T Lee2, Youjun Wang3, Annie Beaudry4, Priyanka Madireddi2, Judith Garriga2, Gabriel G Malouf5, Sarah Dumont5, Elisha J Dettman5, Vazganush Gharibyan5, Saira Ahmed5, Woonbok Chung2, Wayne E Childers6, Magid Abou-Gharbia6, Ryan A Henry7, Andrew J Andrews7, Jaroslav Jelinek2, Ying Cui8, Stephen B Baylin8, Donald L Gill9, Jean-Pierre J Issa10.   

Abstract

Targeting epigenetic pathways is a promising approach for cancer therapy. Here, we report on the unexpected finding that targeting calcium signaling can reverse epigenetic silencing of tumor suppressor genes (TSG). In a screen for drugs that reactivate silenced gene expression in colon cancer cells, we found three classical epigenetic targeted drugs (DNA methylation and histone deacetylase inhibitors) and 11 other drugs that induced methylated and silenced CpG island promoters driving a reporter gene (GFP) as well as endogenous TSGs in multiple cancer cell lines. These newly identified drugs, most prominently cardiac glycosides, did not change DNA methylation locally or histone modifications globally. Instead, all 11 drugs altered calcium signaling and triggered calcium-calmodulin kinase (CamK) activity, leading to MeCP2 nuclear exclusion. Blocking CamK activity abolished gene reactivation and cancer cell killing by these drugs, showing that triggering calcium fluxes is an essential component of their epigenetic mechanism of action. Our data identify calcium signaling as a new pathway that can be targeted to reactivate TSGs in cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26719529      PMCID: PMC4794357          DOI: 10.1158/0008-5472.CAN-14-2391

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Pharmacology of store-operated calcium channels.

Authors:  James W Putney
Journal:  Mol Interv       Date:  2010-08

2.  Calcium-calmodulin kinase II mediates digitalis-induced arrhythmias.

Authors:  Luis A Gonano; Marisa Sepúlveda; Yanina Rico; Marcia Kaetzel; Carlos A Valverde; John Dedman; Alicia Mattiazzi; Martin Vila Petroff
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-10-18

3.  Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression.

Authors:  W Li; J Llopis; M Whitney; G Zlokarnik; R Y Tsien
Journal:  Nature       Date:  1998-04-30       Impact factor: 49.962

4.  Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.

Authors:  M Tailler; L Senovilla; E Lainey; S Thépot; D Métivier; M Sébert; V Baud; K Billot; P Fenaux; L Galluzzi; S Boehrer; G Kroemer; O Kepp
Journal:  Oncogene       Date:  2011-11-21       Impact factor: 9.867

5.  Phosphorylation of distinct sites in MeCP2 modifies cofactor associations and the dynamics of transcriptional regulation.

Authors:  Michael L Gonzales; Sarrita Adams; Keith W Dunaway; Janine M LaSalle
Journal:  Mol Cell Biol       Date:  2012-05-21       Impact factor: 4.272

6.  DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation.

Authors:  Keri Martinowich; Daisuke Hattori; Hao Wu; Shaun Fouse; Fei He; Yan Hu; Guoping Fan; Yi E Sun
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

7.  High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: implications for cancer therapies.

Authors:  Ioannis Prassas; Miltiadis Paliouras; Alessandro Datti; Eleftherios P Diamandis
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

8.  A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene.

Authors:  Ying Cui; Frederick Hausheer; Robert Beaty; Cynthia Zahnow; Jean Pierre Issa; Frederick Bunz; Stephen B Baylin
Journal:  Cancer Res       Date:  2014-05-29       Impact factor: 12.701

9.  Location and function of STIM1 in the activation of Ca2+ entry signals.

Authors:  Thamara Hewavitharana; Xiaoxiang Deng; Youjun Wang; Michael F Ritchie; Gannareddy V Girish; Jonathan Soboloff; Donald L Gill
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

Review 10.  Epigenetic modifications as therapeutic targets.

Authors:  Theresa K Kelly; Daniel D De Carvalho; Peter A Jones
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

View more
  37 in total

Review 1.  DNA Hypomethylating Drugs in Cancer Therapy.

Authors:  Takahiro Sato; Jean-Pierre J Issa; Patricia Kropf
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

2.  Tracing MYC Expression for Small Molecule Discovery.

Authors:  Jutta Steinberger; Francis Robert; Maxime Hallé; David E Williams; Regina Cencic; Neha Sawhney; Dylan Pelletier; Philip Williams; Yasuhiro Igarashi; John A Porco; Abimael D Rodriguez; Brigitte Kopp; Brian Bachmann; Raymond J Andersen; Jerry Pelletier
Journal:  Cell Chem Biol       Date:  2019-03-14       Impact factor: 8.116

Review 3.  Bcl-2 proteins and calcium signaling: complexity beneath the surface.

Authors:  T Vervliet; J B Parys; G Bultynck
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

4.  The Resurrection of Phenotypic Drug Discovery.

Authors:  Wayne E Childers; Khaled M Elokely; Magid Abou-Gharbia
Journal:  ACS Med Chem Lett       Date:  2020-03-06       Impact factor: 4.345

5.  Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Authors:  Noël J-M Raynal; Elodie M Da Costa; Justin T Lee; Vazganush Gharibyan; Saira Ahmed; Hanghang Zhang; Takahiro Sato; Gabriel G Malouf; Jean-Pierre J Issa
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

6.  The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability.

Authors:  Hai Wang; Lin Tian; Jun Liu; Amit Goldstein; Igor Bado; Weijie Zhang; Benjamin R Arenkiel; Zonghai Li; Meng Yang; Shiyu Du; Hong Zhao; David R Rowley; Stephen T C Wong; Zbigniew Gugala; Xiang H-F Zhang
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

Review 7.  Epigenetics and Precision Oncology.

Authors:  Rachael J Werner; Andrew D Kelly; Jean-Pierre J Issa
Journal:  Cancer J       Date:  2017 Sep/Oct       Impact factor: 3.360

8.  Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity.

Authors:  Carly B Garrison; Kristin J Lastwika; Yuzheng Zhang; Christopher I Li; Paul D Lampe
Journal:  J Proteome Res       Date:  2016-11-14       Impact factor: 4.466

Review 9.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

10.  Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.

Authors:  Jiayi Huang; Jian L Campian; Amit D Gujar; Christina Tsien; George Ansstas; David D Tran; Todd A DeWees; A Craig Lockhart; Albert H Kim
Journal:  J Neurooncol       Date:  2018-01-27       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.